References
- DANMAP 2016 Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. ISSN 1600–2032 2016.
- Knudsen JD, Andersen SE. Bispebjerg intervention group for the BI. A multidisciplinary intervention to reduce infections of ESBL- and AmpC-producing, gram-negative bacteria at a University Hospital. PLoS One. 2014;9:e86457. doi:10.1371/journal.pone.0086457.24466106
- Bantar C, Vesco E, Heft C, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. Antimicrob Agents Chemother. 2004;48:392–395. doi:10.1128/AAC.48.2.392-395.2004.14742186
- Petrikkos G, Markogiannakis A, Papaparaskevas J, et al. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital. Int J Antimicrob Agents. 2007;29:34–38. doi:10.1016/j.ijantimicag.2006.08.04217189092
- Peterson LR. REVIEW Antibiotic policy and prescribing strategies for therapy of extended- spectrum b-lactamase-producing Enterobacteri-aceae: the role of piperacillin–tazobactam. Clin Microbiol Infect. 2008;14:181–184. doi:10.1111/j.1469-0691.2007.01864.x18154544
- Gradel KO, Schønheyder HC, Arpi M, Knudsen JD, Østergaard C, Søgaard M. The Danish Collaborative Bacteraemia Network (DACOBAN) database. Clin Epidemiol. 2014;6:301. doi:10.2147/CLEP.S6699825258557
- Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549. doi:10.1007/s10654-014-9930-3.24965263
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-83558716
- Schmidt M, Alba S, Schmidt J, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7::449–90. doi:10.2147/CLEP.S91125
- Friedman ND, Kaye KS, Stout JE, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137:791. doi:10.7326/0003-4819-137-10-200211190-0000712435215
- Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251. doi:10.1016/0895-4356(94)90129-57722560
- DANMAP 2012 -Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. ISSN 1600–2032 2012.
- Ohlin B, Ke Cederberg Å, Forssell H, Solhaug JH, Tveit E. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg. 1999;165:875–884. doi:10.1080/11024159975000761210533765
- Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007;60:855–863. doi:10.1093/jac/dkm27917644532
- Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis. 2014;46:753–762. doi:10.3109/00365548.2014.93745425195648
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 9.0; 2019 Available from: http://www.eucast.org/clinical_breakpoints/. Accessed April 9, 2019.
- Viberg A, Cars O, Karlsson MO, Jönsson S. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. J Clin Pharmacol. 2008;48:1270–1281. doi:10.1177/009127000832092318974282
- Carlier M, Noe M, Roberts JA, et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. J Antimicrob Chemother. 2014;69:2797–2803. doi:10.1093/jac/dku19524917580
- Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol. 2015;1–6. doi:10.1016/j.coph.2015.06.002